As filed with the Securities and Exchange Commission on February 25, 2015

 

Registration No. 333-  

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

bluebird bio, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

(State or Other Jurisdiction

of Incorporation or Organization)

13-3680878

(I.R.S. Employer Identification No.)

 

bluebird bio, Inc.

150 Second Street

Cambridge, MA 02141

(339) 499-9300

(Address of Principal Executive Offices)

 

2013 Stock Option and Incentive Plan

(Full Title of the Plan)
______________________________________________________________

 

Nick Leschly

President and Chief Executive Officer

bluebird bio, Inc.

150 Second Street

Cambridge, MA 02141

(339) 499-9300

(Name and Address of Agent For Service)

 

Copy  to:

Michael H. Bison, Esq.

Goodwin Procter LLP
Exchange Place

53 State Street

Boston, Massachusetts 02109

(617) 570-1000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  x

 

Accelerated filer  ¨         

 

 

 

Non-accelerated filer  ¨

(Do not check if a smaller reporting company)

 

Smaller reporting company  ¨

 


 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

Title of Securities

to be Registered

Amount

to be

Registered(1)

Proposed Maximum

Offering Price

per Share(2)

Proposed Maximum

Aggregate

Offering Price

Amount of

Registration

Fee(3)

2013 Stock Option and Incentive Plan

Common Stock, $0.01 par value per share

1,293,592 shares

$92.93

$120,207,037.00

$13,969.00

 

(1)

Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of common stock which become issuable under the above-named plan by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. Pursuant to Rule 416(c) under the Securities Act, this registration statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plan described herein.

(2)

The price of $92.93 per share, which is the average of the high and low sale prices of the common stock of the registrant on the NASDAQ Global Select Market on February 20, 2015, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and has been used as these shares are without a fixed price.

(3)

Calculated pursuant to Section 6(b) of the Securities Act.

_________________________

 

 

 


 

This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 (SEC File No. 333-189560) of the Registrant is effective.  The information contained in the Registrant's registration statement on Form S-8 (SEC File No. 333-189560) is hereby incorporated by reference pursuant to General Instruction E.

 

 

Part II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

 

 

Item 8.           Exhibits.

 

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the 25th day of February, 2015.

 

 

 

bluebird bio, Inc.

 

 

 

 

 

 

By:

/s/ Nick Leschly

 

 

 

Nick Leschly

 

 

 

President and Chief Executive Officer

 

POWER OF ATTORNEY

 

We, the undersigned officers and directors of bluebird bio, Inc., hereby severally constitute and appoint Nick Leschly and James DeTore, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated below on the 25th day of February, 2015.

 

 

Name

  

Title

  

 

 

/s/ Nick Leschly

  

President, Chief Executive Officer and Director

  

Nick Leschly

 

(Principal Executive Officer)

 

 

 

/s/ James M. DeTore

  

Chief Financial Officer and Treasurer

  

James M. DeTore

 

(Principal Financial Officer)

 

 

 

/s/ Eric Sullivan

  

Senior Director, Finance

  

Eric Sullivan

 

(Principal Accounting Officer)

 

 

 

/s/ Robert I. Tepper, M.D.

  

Director

  

Robert I. Tepper, M.D.

 

 

 

 

 

/s/ Steven Gillis, Ph.D.

  

Director

  

Steven Gillis, Ph.D.

 

 

 

 

 

/s/ Daniel S. Lynch

  

Director

  

Daniel S. Lynch

 

 

 

 

 

/s/ James Mandell, M.D.

  

Director

  

James Mandell, M.D.

 

 

 

 

 

/s/ John M. Maraganore, Ph.D.

  

Director

  

John M. Maraganore, Ph.D.

 

 

 

 


 

Name

  

Title

  

 

 

/s/ Wendy L. Dixon, Ph.D.

  

Director

  

Wendy L. Dixon, Ph.D.

 

 

 

 

 

/s/ David P. Schenkein, M.D.

  

Director

  

David P. Schenkein, M.D.

 

 

 

 

 

/s/ Mark Vachon

  

Director

  

Mark Vachon

 

 

 

 


 

EXHIBIT INDEX

 

Exhibit No.

 

Description

5.1

*

Opinion of Goodwin Procter LLP.

23.1

*

Consent of Goodwin Procter LLP (included in Exhibit 5.1).

23.2

*

Consent of Ernst & Young LLP.

24.1

 

Power of attorney (included on signature page).

__________________________

*

Filed herewith.